



Procedure	Result	Units	Ref Interval	Accession	Collected	Received	Reported/ Verified
Mi-2 (nuclear helicase protein) Antibody	Negative		[Negative]	16-301-900129	27-Oct-16 15:21:00	27-Oct-16 15:21:00	27-Oct-16 16:14:35
P155/140 (TIF1-gamma) Antibody	Positive *		[Negative]	16-301-900129	27-Oct-16 15:21:00	27-Oct-16 15:21:00	27-Oct-16 16:14:35
TIF1-gamma Antibody	Positive *			16-301-900129	27-Oct-16 15:21:00	27-Oct-16 15:21:00	27-Oct-16 16:14:35
SAE1 (SUMO activating enzyme) Antibody	Negative			16-301-900129	27-Oct-16 15:21:00	27-Oct-16 15:21:00	27-Oct-16 16:14:35
MDA5 (CADM-140) Antibody	Negative			16-301-900129	27-Oct-16 15:21:00	27-Oct-16 15:21:00	27-Oct-16 16:14:35
NXP-2 (Nuclear matrix protein-2) Ab	See Note			16-301-900129	27-Oct-16 15:21:00	27-Oct-16 15:21:00	27-Oct-16 16:14:35
Dermatomyositis Interpretive Information	See Note			16-301-900129	27-Oct-16 15:21:00	27-Oct-16 15:21:00	27-Oct-16 16:14:35

27-Oct-16 15:21:00 TIF1-gamma Antibody
 TIF-1 gamma positive by line immunoassay. Bands corresponding to 155/140 or 155 KDa observed by immunoprecipitation. Profile consistent with TIF-1 gamma antibody positivity.

27-Oct-16 15:21:00 SAE1 (SUMO activating enzyme) Antibody
 SAE1 antibody negative by line immunoassay. No bands corresponding to 90 and 40 Kda observed by immunoprecipitation.

27-Oct-16 15:21:00 MDA5 (CADM-140) Antibody
 MDA-5 antibody negative by line immunoassay. No band corresponding to 140 KDa observed by immunoprecipitation.

27-Oct-16 15:21:00 NXP-2 (Nuclear matrix protein-2) Ab
 NXP-2 borderline by line immunoassay. No band corresponding to 140 KDa observed by immunoprecipitation. Strong clinical correlation recommended.

27-Oct-16 15:21:00 Dermatomyositis Interpretive Information:
 INTERPRETIVE INFORMATION: Dermatomyositis Panel

If present, myositis-specific antibodies (MSA) are specific for myositis, and may be useful in establishing diagnosis as well as prognosis. MSAs are generally regarded as mutually exclusive with rare exceptions; the occurrence of two or more MSAs should be carefully evaluated in the context of patient's clinical presentation. Myositis-associated antibodies (MAA) may be found in patients with CTD including overlap syndromes, and are generally not specific for myositis. The following table will help in identifying the association of any antibodies found as either MSAs or MAAs.

Antibody Specificity	MSA	MAA
Mi-2 (nuclear helicase protein) Antibody	X	
P155/140 (TIF1-gamma) Antibody	X	
TIF1-gamma Antibody	X	
SAE1 (SUMO activating enzyme) Antibody	X	
MDA5 (CADM-140) Antibody	X	
NXP-2 (Nuclear matrix protein-2) Ab	X	

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab